Crystalline derivatives of (E)-2-(5-chlorothien-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide

US7645338B2 · kind B2 · utility

Assignee

• Glaxo Group Limited · GB

Inventors

• Philip C. Dell 'Orco · King of Prussia, US
• Henry Anderson Kelly · Stevenage, GB
• Gita Punjabhai Shah · Stevenage, GB
• Nigel S. Watson · Martinez, US
• Robert John Young · Stevenage, GB

Key dates

• Filing date: Dec 4, 2003
• Grant date: Jan 12, 2010
• Expiry date: Aug 19, 2024

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention includes (E)-2-(5-Chlorothien-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide in substantially crystalline form, pharmaceutical formulations thereof, processes for preparing it, and its use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.